# Study to Assess the Safety and Effectiveness of Beltaven® in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp.

> **NCT07309822** · — · RECRUITING · sponsor: **Probelte Pharma S.L.U.** · enrollment: 27 (estimated)

## Conditions studied

- Allergy

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07309822
- **Lead sponsor:** Probelte Pharma S.L.U.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2031-05
- **Final completion:** 2031-12
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07309822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07309822, "Study to Assess the Safety and Effectiveness of Beltaven® in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07309822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*